Hellow guys, Welcome to my website, and you are watching ANDA Postapproval Changes: Best Practices and Strategies to Avoid Common Quality Assessment Issues. and this vIdeo is uploaded by U.S. Food and Drug Administration at 2021-05-14T07:10:31-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | ANDA Postapproval Changes: Best Practices and Strategies to Avoid Common Quality Assessment Issues |
| Video Uploader | Video From U.S. Food and Drug Administration |
| Upload Date | This Video Uploaded At 14-05-2021 14:10:31 |
| Video Discription | Niles Ron, PhD, MBA, Branch Chief for the Division of Post-Marketing Activities II, discusses common post-marketing quality assessment issues, strategies to avoid them, and best practices. Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021 -------------------- FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research. Upcoming Training - https://www.fda.gov/cdersbia SBIA Listserv - https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352 SBIA 2021 Playlist - https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD SBIA LinkedIn: https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance SBIA Training Resources - https://www.fda.gov/cdersbialearn Twitter - https://twitter.com/FDA_Drug_Info Email - CDERSBIA@fda.hhs.gov Phone - (301) 796-6707 I (866) 405-5367 |
| Category | Education |
| Tags | FDA | CDER | SBIA | GDF | Generic Drug Forum | Generic | ANDA | OGD |
